Diabetic Retinopathy — VA Disability Rating Criteria (DC 6040)

Diagnostic Code 6040 · 38 CFR §4.79

What Is It?

DC 6040 was added to 38 CFR 4.79 by the rule effective 13 May 2018, and it appears as a bare line — "6040 Diabetic retinopathy" — with an empty rating column. The criteria come from the section's opening instruction, which directs that unless otherwise directed, diseases of the eye are evaluated under the General Rating Formula for Diseases of the Eye. That formula pays whichever is higher of two bases: visual impairment due to the condition, or documented incapacitating episodes counted as treatment visits over the past twelve months. The definition of an incapacitating episode is the part of this code most often got wrong, and getting it right is usually worth a rating. Note (1) to the formula reads: "For the purposes of evaluation under 38 CFR 4.79, an incapacitating episode is an eye condition severe enough to require a clinic visit to a provider specifically for treatment purposes." There is no requirement of prescribed bed rest and no threshold measured in weeks. Note (2) names exactly the treatments a retinopathy patient receives — "systemic immunosuppressants or biologic agents; intravitreal or periocular injections; laser treatments; or other surgical interventions." Anti-VEGF injections and panretinal photocoagulation are on that list by name. That matters more here than under almost any other eye code, because the standard of care for proliferative retinopathy and diabetic macular oedema is a series of injections, often monthly for a period and then at intervals. A veteran receiving monthly intravitreal injections crosses the seven-visit line for 60 percent within a year, on treatment visits alone, with no reference to acuity at all. The count is of visits in the past twelve months, so it is worth assembling before an examination rather than after. Diabetic retinopathy is damage to the retinal microvasculature from chronic hyperglycaemia. It progresses from mild non-proliferative changes through moderate and severe non-proliferative disease to proliferative retinopathy, where fragile new vessels grow and bleed; diabetic macular oedema can occur at any stage and is the more common cause of vision loss. For veterans with service-connected diabetes mellitus it is the classic secondary claim, and it is rated separately from the diabetes itself. Where the claim runs on visual impairment instead of visits, the measurements come from 38 CFR 4.75 through 4.78 and the visual codes at the end of 4.79, subject to the 30 percent one-eye ceiling in 38 CFR 4.75(d) unless the eye is anatomically lost.

Rating Criteria

Evidence Needed

The highest-value document is an itemised, dated list of eye treatment visits over the last twelve months — every intravitreal anti-VEGF injection, every laser session, every vitrectomy or other surgical intervention. That list is what the rating table is scored against, and it is usually easier to obtain than it is to argue about acuity. Build the visual-impairment side alongside it: dilated fundus examination staging the retinopathy as non-proliferative or proliferative, optical coherence tomography quantifying macular oedema, fundus photography, fluorescein angiography where performed, best-corrected acuity, and formal perimetry where laser has cost peripheral field. For service connection, the diabetes diagnosis and a medical opinion linking the retinopathy to it; haemoglobin A1c history supports the causal narrative without being required by the rating criteria.

C&P Exam Tips

Bring the dated treatment list and give it to the examiner. Describing your treatment as ongoing injections produces no count, and the count is the rating. Ask that the examination record the stage of retinopathy in each eye and whether macular oedema is present, since those determine the treatment schedule going forward. Have the exam done dilated. If panretinal photocoagulation has been performed, mention it specifically and ask for visual-field testing — extensive laser characteristically costs peripheral field and night vision, which an acuity chart will never show. Do not describe your injection recovery in terms of bed rest; the eye formula counts the visit itself, and framing it as bed rest invites the wrong standard.

How to File

File as secondary to service-connected diabetes mellitus, with the diabetes rating decision, current retinopathy findings, and an opinion linking the two. Submit both rating bases together — the treatment-visit list and the visual-impairment testing — because the formula requires VA to pay whichever is higher and a decision addressing only one has not made that comparison. Ask that both eyes be staged separately. Diabetic retinopathy is rated separately from diabetes, so the two evaluations combine under 38 CFR 4.25 rather than one absorbing the other.

Common Mistakes

The single most expensive mistake on this code is arguing incapacitating episodes in weeks of prescribed bed rest. That standard comes from the intervertebral disc formula in 38 CFR 4.71a and has never applied to the eye. Section 4.79 counts clinic visits for treatment, and Note (2) lists intravitreal injections and laser among the qualifying treatments — so a veteran on monthly injections who argues bed rest can talk themselves out of a 60 percent evaluation they already meet. The second mistake is not claiming retinopathy separately from diabetes at all, on the assumption it is covered by the diabetes rating. The third is failing to bring the dated visit list, which converts an easily provable count into a matter of recollection. Finally, veterans who have had extensive laser rarely request visual-field testing, though peripheral field loss is exactly what that treatment costs.

Frequently Asked Questions

Can I get a separate rating for diabetic retinopathy on top of my diabetes rating?

Yes. Diabetic retinopathy is its own diagnostic code, DC 6040, and is evaluated separately from diabetes mellitus. The two evaluations then combine under 38 CFR 4.25. Filing the retinopathy as though it were a symptom of the diabetes, rather than as its own secondary claim, is a common way for the separate evaluation to go unmade.

What counts as an incapacitating episode for diabetic retinopathy?

A clinic visit to a provider specifically for treatment. Note (1) to the General Rating Formula defines it that way for all of 38 CFR 4.79, with no bed-rest element and no minimum duration. Note (2) lists intravitreal or periocular injections, laser treatments, systemic immunosuppressants or biologic agents, and other surgical interventions as examples of qualifying treatment.

I get monthly anti-VEGF injections. What rating does that support?

Seven or more treatment visits in the past twelve months is the 60 percent criterion, and a monthly injection schedule reaches that on visits alone. Five or six visits is 40 percent, three or four is 20 percent, and one or two is 10 percent. Bring the dated record of each injection; the table is scored on the count, not on a description of the schedule.

Does the rating depend on how bad my vision is?

Only if visual impairment produces a higher figure than the visit count. The formula's opening line directs evaluation on either visual impairment or incapacitating episodes, whichever results in a higher evaluation. Veterans with good acuity and heavy treatment are often rated higher on visits; veterans with substantial vision loss and few visits are rated on impairment.

Should I file if my retinopathy is still early?

Yes. Establishing service connection now means later increases are decided on severity alone, without re-litigating the link to diabetes. Even a non-compensable evaluation fixes the connection and the effective date. Retinopathy is progressive in most people whose diabetes is long-standing, and the claim gets no easier for waiting.

I had panretinal laser. Why should I ask for a visual-field test?

Because that is where its cost shows up. Panretinal photocoagulation treats the periphery to protect central vision, and the trade is peripheral field and night vision. Acuity testing will not detect it. Visual field defects are separately evaluated under DC 6080, and a claim examined only with an acuity chart leaves that evaluation unmade.